Upgrade to Finviz Elite: Get our fastest platform speed, real-time data, and unlimited screening & charting. Start Free Trial

GENB

Generate Biomedicines Inc

May 28 • 01:03PM ET

13.25

+0.17 1.30 %

Healthcare • Biotechnology • USA • Small • NASD

Peers: KYMR RYTM APGE NUVL BMRN INCY KRYS VKTX AXSM NBIX

| Held by: ARKG VTI ONEQ VXF GNMX

Scroll to Statements

Index	-	P/E	-	EPS (ttm)	-	Insider Own	57.39%	Shs Outstand	128.19M	Perf Week	1.77%
Market Cap	1.70B	Forward P/E	-	EPS next Y	-2.15	Insider Trans	14.65%	Shs Float	54.63M	Perf Month	6.26%
Enterprise Value	1.25B	PEG	-	EPS next Q	-0.51	Inst Own	19.40%	Short Float	6.32%	Perf Quarter	-
Income	-	P/S	-	EPS this Y	50.83%	Inst Trans	37.99%	Short Ratio	6.48	Perf Half Y	-
Sales	-	P/B	3.30	EPS next Y	4.03%	ROA	-	Short Interest	3.45M	Perf YTD	4.74%
Book/sh	4.02	P/C	3.29	EPS next 5Y	27.56%	ROE	-	52W High	16.75 -20.89%	Perf Year	-
Cash/sh	4.03	P/FCF	-	EPS past 3/5Y	- -	ROIC	-	52W Low	11.00 20.45%	Perf 3Y	-
Dividend Est.	-	EV/EBITDA	-	Sales past 3/5Y	- -	Gross Margin	-	Volatility	8.85% 9.31%	Perf 5Y	-
Dividend TTM	-	EV/Sales	-	EPS Y/Y TTM	-	Oper. Margin	-	ATR (14)	1.24	Perf 10Y	-
Dividend Ex-Date	-	Quick Ratio	9.17	Sales Y/Y TTM	-	Profit Margin	-	RSI (14)	47.81	Recom	1.00
Dividend Gr. 3/5Y	- -	Current Ratio	9.17	EPS Q/Q	-	SMA20	-6.15%	Beta	-	Target Price	25.40
Payout	-	Debt/Eq	0.13	Sales Q/Q	-	SMA50	1.40%	Rel Volume	0.74	Prev Close	13.08
Employees	312	LT Debt/Eq	0.10	Earnings	May 07 BMO	SMA200	2.66%	Avg Volume	533.09K	Price	13.25
IPO	Feb 27, 2026	Option/Short	No / Yes	EPS/Sales Surpr.	-110.63% 36.83%	Trades		Volume	223,351	Change	1.30%

Date	Action	Analyst	Rating Change	Price Target Change
Apr-13-26	Initiated	H.C. Wainwright	Buy	$16
Mar-24-26	Initiated	Piper Sandler	Overweight	$24
Mar-24-26	Initiated	Morgan Stanley	Overweight	$20
Mar-24-26	Initiated	Guggenheim	Buy	$30
Mar-24-26	Initiated	Goldman	Buy	$26
Mar-24-26	Initiated	Cantor Fitzgerald	Overweight

May-07-26 06:24AM	Generate Biomedicines: Q1 Earnings Snapshot (Associated Press) -11.21%
06:16AM	Generate Biomedicines, Inc. Reports First Quarter 2026 Financial Results and Provides Business Update (PR Newswire)

Generate Biomedicines, Inc. is a clinical-stage generative biology company pioneering the AI revolution in biotechnology and drug design and development. The company was founded in 2018, and is headquartered in Somerville, MA.

Co-founder & Independent Chair of the BoardDr. Noubar B. Afeyan Ph.D.

CEO & DirectorMr. Michael T. Nally M.B.A.

M.D.Dr. Jason E. Silvers J.D.

Co-Founder & CTODr. Gevorg Grigoryan Ph.D.

Co-FounderMs. Molly Gibson Ph.D.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Nally Michael	Chief Executive Officer	Mar 04 '26	Buy	12.00	20,000	240,000	572,707	Mar 06 04:55 PM
Grous Beth	Chief People Officer	Mar 02 '26	Buy	16.00	300	4,800	300	Mar 02 06:05 PM
Silvers Jason	President & CFO	Mar 02 '26	Buy	16.00	2,000	32,000	1,000	Mar 02 05:54 PM
AFEYAN NOUBAR	Director	Mar 02 '26	Buy	16.00	4,687,500	75,000,000	15,264,724	Mar 02 05:52 PM
Mendillo Jane L	Director	Mar 02 '26	Buy	16.00	1,500	24,000	1,500	Mar 02 05:47 PM
AFEYAN NOUBAR	Director	Mar 02 '26	Buy	16.00	4,687,500	75,000,000	15,264,724	Mar 02 05:42 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

GENB

Generate Biomedicines Inc

Upgrade your Finviz experience